Super-enhancers comprise dense transcription factor platforms highly enriched for active chromatin marks. A paucity of functional data led us to investigate the role of super-enhancers in the mammary gland, an organ characterized by exceptional gene regulatory dynamics during pregnancy. ChIP-seq analysis for the master regulator STAT5A, the glucocorticoid receptor, H3K27ac and MED1 identified 440 mammary-specific super-enhancers, half of which were associated with genes activated during pregnancy. We interrogated the Wap super-enhancer, generating mice carrying mutations in STAT5-binding sites within its constituent enhancers. Individually, the most distal site displayed the greatest enhancer activity. However, combinatorial mutation analysis showed that the 1,000-fold induction in gene expression during pregnancy relied on all enhancers. Disabling the binding sites of STAT5, NFIB and ELF5 in the proximal enhancer incapacitated the entire super-enhancer. Altogether, these data suggest a temporal and functional enhancer hierarchy. The identification of mammary-specific super-enhancers and the mechanistic exploration of the Wap locus provide insights into the regulation of cell-type-specific expression of hormone-sensing genes.
The main purpose of the mammary gland is to produce large quantities of milk to support newborns. The milk-secreting alveolar epithelium, absent in the virgin state, is established during pregnancy and is considerably remodeled upon cessation of lactation 1 . Proliferation and differentiation of mammary alveoli during pregnancy is controlled by the hormones progesterone 2 and prolactin 3, 4 through the transcription factors STAT5 (refs. 5, 6) and ELF5 (ref. 7) . STAT5 (refs. 8,9) has emerged as the critical transcription factor activating genes encoding milk proteins, and other differentiation-associated proteins linked to milk secretion, by up to 10,000-fold during pregnancy 10 . The ten most abundant mRNAs encoding milk proteins account for more than 90% of the mRNA in mammary gland 11, 12 , and expression of the respective genes is synergistically induced by prolactin and glucocorticoids 13 , making these genes an ideal system to investigate underlying transcriptional regulation.
Traditionally, transgenic mice have been used to identify sequences conveying mammary specificity and hormonal responsiveness [13] [14] [15] [16] [17] [18] [19] . Although informative, the transgenes used contained only limited promoter and upstream sequences, which conveyed mammaryrestricted expression but normal hormonal regulation during pregnancy, and expression levels were not achieved. These results suggest that enhancers and insulators were located outside the sequences used for these transgenes. Putative regulatory elements in the genome can now be identified using ChIP-seq analyses for transcription factors and specific histone modifications such as acetylation of histone H3 at lysine 27 (H3K27ac) [20] [21] [22] [23] . This permits a more accurate approach in the genetic analysis of these sequences.
The emerging concept of super-enhancers proposes that lineagespecific genes are under the control of special enhancer clusters, which are characterized by the presence of several densely occupied transcription factor platforms and extended H3K27ac marking 24, 25 . Although super-enhancers have been reported in a plethora of cell types , there is scant genetic support of their unique biological relevance. Several hundred genes are expressed specifically in mammary tissue under the control of prolactin 10 , making them an ideal test system for the concept of super-enhancers. Here we have integrated ChIP-seq analyses for the mammary master regulator STAT5A, glucocorticoid receptor (GR), the Mediator complex subunit MED1 and the active chromatin mark H3K27ac to identify putative mammary-specific super-enhancers. To investigate the biological relevance of super-enhancers, we focused on the one associated with Wap 47 , a gene highly expressed in mammary tissue and induced by more than 1,000-fold during pregnancy 48 . We mutated constituent enhancers, individually and in combination, within the Wap super-enhancer, determined their respective importance, and identified a temporal and functional hierarchy among them.
RESULTS

Identification of mammary-specific super-enhancers
In search of mammary-specific super-enhancers, we conducted ChIP-seq experiments for STAT5A, a master regulator in mammary Hierarchy within the mammary STAT5-driven Wap super-enhancer epithelium 5, 6 , H3K27ac, GR and MED1. Mammary tissue was initially analyzed at lactation when mammary-specific genes are highly expressed. On the basis of the colocalization of transcription factor binding and H3K27ac marks and defined 'stitch' sizes 46 (Fig. 1a and Supplementary Figs. 1-3) , we identified approximately 580 super-enhancers. After removing STAT5 super-enhancers common to mammary tissue and either liver or T cells, we obtained 440 mammary-specific super-enhancers, encompassing a total of 2,712 individual enhancers ( Fig. 1a and Supplementary Table 1 ). These 440 super-enhancers were exclusively identified on the basis of ChIP-seq experiments, and their biological function has not been experimentally validated.
To assess the functional relevance of super-enhancers in lactating mammary tissue, we used RNA-seq data 10 and compared the expression of genes associated with super-enhancers to that of genes associated with lone STAT5 enhancers ( Fig. 1b) . Whereas the median expression level of genes linked to lone enhancers was ~14 FPKM (mean of ~31 FPKM), the median expression level was ~27 FPKM (mean of ~5,931 FPKM) for genes associated with superenhancers. Gene set enrichment analysis (GSEA) demonstrated that super-enhancers were preferentially associated with genes with STAT5-dependent expression ( Fig. 1c) . The expression of approximately 35% of super-enhancer-associated genes was induced by more than twofold by STAT5 ( Supplementary Table 1) , and approximately 50% of the genes associated with super-enhancers were also induced during pregnancy. Notably, although most highly induced genes were associated with super-enhancers, some, such as Aldoc, were linked to lone enhancers (Supplementary Fig. 3 ).
Next, we examined whether the expression of super-enhancerassociated genes was specifically elevated in mammary tissue.
We analyzed expression in mammary tissue at day 1 of lactation, in T helper type 1 (T H 1) cells and in liver tissue, all of which are targets of cytokines that activate STAT5. Whereas the expression level for super-enhancer-associated genes in mammary tissue averaged 27 FPKM (mean of ~5,931 FPKM), the average expression level was ~12 FPKM (mean of ~31 FPKM) in T cells and ~6 FPKM (mean of ~28 FPKM) in liver ( Fig. 1d ). Although these findings demonstrate a preference for mammary expression among genes associated with mammary super-enhancers, they also show that some of these genes are expressed in non-mammary cells under cytokine control. Approximately 50% of super-enhancer-associated genes were induced during pregnancy through STAT5, and their expression was highly enriched in mammary tissue ( Supplementary Table 1 ) at a median of ~43 FPKM (mean of ~11,388 FPKM) ( Fig. 1e, left) . In contrast, the expression of genes not induced during pregnancy was only slightly enriched in mammary tissue ( Fig. 1e, right) .
Establishment of mammary super-enhancers during pregnancy
Enhancers are characterized by the binding of several transcription factors at so-called hotspots 43, 49 . A motif search (see the Online Methods for details) identified an enrichment of predicted binding sites for ELF5 and NFIB ( Fig. 2a) , transcription factors critical to mammary development 7, 13, 50 . ChIP-seq experiments validated binding of NFIB and ELF5 to enhancers also occupied by STAT5A, GR and MED1 (Fig. 2b,c) , as exemplified by the Wap and Olah loci ( Fig. 2b and Supplementary Fig. 4 ).
We hypothesized that mammary super-enhancers are established during pregnancy, a time frame during which the expression of mammary-specific genes greatly increases. To examine this hypothesis, we performed ChIP-seq for STAT5A, GR, NFIB, ELF5, MED1 and The box plots show that expression of the 384 genes associated with the mammary-specific super-enhancer is significantly elevated at day 1 of lactation, when compared to T cells and liver tissue. (e) Super-enhancerassociated genes were categorized as genes induced by at least twofold between day 6 of pregnancy and day 1 of lactation (198) and genes that were not induced (186). Notably, induced genes exhibit lineage specificity, and their expression in T cells and liver is much lower than in mammary tissue.
A r t i c l e s H3K27ac on mammary tissue at day 13 of pregnancy, before the activation of key genes including Wap. Whereas 7% (32) of all superenhancers were not occupied at day 13 of pregnancy and seemed to be established only at day 1 of lactation, some constituent enhancers within the remaining 93% (408) of super-enhancers showed limited transcription factor occupancy at day 13 of pregnancy ( Fig. 3a) . In 56% of the super-enhancers, less than half of the ChIP-seq peaks were established at day 13 of pregnancy, 32% of the super-enhancers had coverage for more than half of the peaks and in 5% of the superenhancers all peaks were already fully established. The sensitivity of ChIP-seq experiments depends on the quality of the antibodies used, and it is possible that the data displayed in Figure 3a underestimate transcription factor binding. Next, we assessed to what extent the temporal gain in transcription factor binding to these enhancers translated into activation of associated genes (Fig. 3b) . Genes associated with super-enhancers without transcription factor binding (group I) or that were only partially occupied (groups II and III) at day 13 of pregnancy were characterized by higher levels of induction than genes already fully occupied at this stage (group IV). Furthermore, genes associated with fully established super-enhancers at day 13 of pregnancy showed higher levels of expression ( Supplementary Fig. 5 ). Super-enhancers without apparent STAT5A occupancy at day 13 of pregnancy showed the highest level of induction, followed by those with less than 50% occupancy and those with more than 50% occupancy ( Fig. 3c, left) . In contrast, super-enhancers associated with non-induced genes showed equivalent expression patterns across the groups (Fig. 3c, right) . The individual enhancers within a given super-enhancer were frequently not established in concert during pregnancy but were established in a seemingly defined temporal order, suggesting that they might differentially sense prolactin and, possibly, transcription factor concentrations. Notably, some individual enhancers within super-enhancers were already occupied during pregnancy, before the activation of the associated genes. To attain a better understanding of the temporal progression in the establishment of mammary-specific super-enhancers, we focused on the tripartite enhancer of Wap 47 , a gene induced by more than 1,000-fold during pregnancy 13, 51 . The Wap super-enhancer consists of three constituent enhancers, with one (E1) already occupied by STAT5A, GR, NFIB, ELF5 and MED1 at mid pregnancy ( Fig. 3d and Supplementary Fig. 6a ). In contrast, E2 and E3 were fully occupied only at the onset of lactation. Similarly, one of the three individual enhancers within the Glycam1 super-enhancer was already established during pregnancy, before transcriptional activation of the gene (Fig. 3e) . These findings suggest that individual enhancers within mammary-specific super-enhancers may have unique properties and differentially sense hormonal cues as pregnancy progresses. Moreover, enhancers already occupied in early pregnancy, such as E1 in the Wap super-enhancer, seem generally unable to activate mammary-specific gene expression by themselves. The window between day 13 of pregnancy and day 1 of lactation is characterized by epithelial differentiation with little proliferation, suggesting that the establishment of super-enhancers is the result of cellular differentiation. Expression of Krt8 and Krt18, markers of mammary secretory epithelium, was equivalent between day 13 of pregnancy and day 1 of lactation ( Supplementary Table 1 ). To further strengthen this evidence, we conducted STAT5A and H3K27ac ChIPseq experiments at days 14 and 16 of pregnancy, stages that are distinguished by their differentiation status, as evidenced by the 100-fold activation of Wap gene expression ( Fig. 3f,g and Supplementary  Fig. 6b ). Whereas E1, but not E2 and E3, was occupied by STAT5A at day 14 of pregnancy, binding at all sites was secured by day 16, indicating that the Wap super-enhancer is fully activated within this narrow window. Although the expansion of mammary epithelium between days 14 and 16 of pregnancy was negligible and the respective tissues had an equivalent appearance ( Supplementary Fig. 7) , we analyzed the gain of signal specific to mammary epithelium and still compared specific chromatin marks in intact tissue and enriched mammary epithelial cells (MECs; Supplementary Fig. 8 ).
Hierarchy within the mammary-specific Wap super-enhancer
The progressive establishment of mammary-specific super-enhancers during pregnancy parallels the activation of some, but not all, associated genes, suggesting a possible causal relationship. Because the creation of mammary alveoli is strictly dependent upon STAT5 (refs. 6,52), it has not been possible to investigate the in vivo role of STAT5 in the establishment of individual mammary-specific enhancers 10 in tissue devoid of STAT5. To study the contribution of individual STAT5binding sites within a mammary-specific super-enhancer, we focused on Wap, which is activated by more than 1,000-fold during pregnancy 13, 51 . First, we individually deleted the γ-interferon-activated sequence (GAS) motif in each of the three putative STAT5-bound enhancers (E1-E3) ( Fig. 4a and Supplementary Fig. 9 ). The proximal E1 site was mutated using CRISPR/Cas9 genome editing, and the E2 and E3 sites were deleted using TALEN technology (Fig. 4b) .
Mammary tissue from homozygous-mutant mice was analyzed at the onset of lactation. Deletion of the proximal STAT5 enhancer site (∆E1) resulted in a 62% reduction in Wap mRNA levels, loss of E2 (∆E2) resulted in a 48% reduction and inactivation of the distal site (∆E3) led npg A r t i c l e s to a reduction of 91% (Fig. 4c) . These findings indicate that the three STAT5-bound enhancer units, despite their similar transcription factor occupancy and H3K27ac profiles, possess different roles in vivo, suggesting unique contributions for STAT5 at these sites.
Although highly informative, this study did not explore possible interactions between the three constituent enhancers that would account for the 1,000-fold induction in Wap expression. To investigate such interactions, we conducted successive gene targeting using CRISPR/Cas9 editing and generated mice carrying different combinations of mutations. Because E1 is established before Wap gene activation, preceding the formation of E2, we explored the functional relationship between these enhancers. E1-mutant embryos were targeted at E2, and ∆E1a/∆E2 mice were generated. The combined loss of these two STAT5-binding sites resulted in an 87% reduction in Wap expression ( Fig. 4c) , less than what had been observed for the E3 mutant. This finding provides further evidence of the prominent status of the distal E3 enhancer. An indication that the E2 and E3 enhancers might be the key to the extraordinary activation of Wap came from the observation that STAT5A occupancy of these sites coincided with the 100-fold activation of Wap between days 14 and 16 of pregnancy ( Fig. 3f,g) . To test this hypothesis, we targeted E2 in E3-mutant embryos and generated mice lacking both sites (∆E2/∆E3 mutants). Wap expression in these mice was reduced by ~95% relative to wild-type mice (Fig. 4c) . Although the induction of Wap from these enhancers is extraordinary in comparison to that of other enhancer-dependent genes, this still does not account for the 1,000-fold induction in expression of endogenous Wap. To test whether the combination of all three sites is necessary for full induction, we generated mice devoid of all three STAT5-binding sites. E1-mutant embryos were targeted for E2 and E3, and homozygous mice (∆E1a/ ∆E2/∆E3) were generated and analyzed. In the absence of the three c d e f g Figure 3 Assembly at constituent enhancers in mammary-specific super-enhancers during pregnancy. (a) Seven percent of super-enhancers have no established peaks at day 13 of pregnancy, 56% have less than half their enhancers occupied, 32% have more than half their enhancers occupied and 5% are already established. (b) Genes associated with progressive super-enhancers (418) show higher levels of induction than those fully occupied at day 13 of pregnancy (22) . Median, middle bar inside the box; IQR, 50% of the data; whiskers, 1.5 times the IQR. (c) Progressive enhancers associated with genes induced during pregnancy show higher levels of induction (left) than those associated with genes that are not induced (right). Super-enhancers having no established enhancers at day 13 of pregnancy show the highest level of induction, followed by those with less than 50% and more than 50% of their enhancers already occupied. (d) Establishment of enhancers in the mammary-specific Wap super-enhancer. Only E1 is occupied by mammary-enriched transcription factors at day 13 of pregnancy, whereas E2 and E3 are exclusively occupied at day 1 of lactation. Data are representative of biological duplicates. (e) Progressive establishment of the mammary-specific Glycam1 super-enhancer. One of three individual enhancers (asterisk) is already occupied by mammary transcription factors at day 13 of pregnancy, and all three enhancers are fully occupied at lactation. (f) Establishment of individual enhancers in the mammary-specific Wap super-enhancer across different pregnancy stages. Only E1 is occupied by STAT5A and has H3K27ac marks at days 13 and 14 of pregnancy, whereas all three enhancers are fully occupied at day 16 of pregnancy and day 1 of lactation. (g) Wap mRNA levels in mammary tissue during different stages of pregnancy. A two-tailed unpaired Student t test was used to evaluate statistical significance: **P < 0.001. L1, n = 6; p16, p14 and p13, n = 3. The Csn locus served as a control (supplementary Fig. 6 ). A r t i c l e s STAT5-binding sites, Wap expression at day 1 of lactation was reduced to ~0.1% in comparison to wild-type control (Fig. 4c) . To determine whether this unprecedented enhancer activity mirrored the induction of Wap at mid pregnancy, the stage when E2 and E3 are bound by STAT5A and other transcription factors and acquire extensive H3K27ac, we compared Wap expression in tissues from ∆E1a/∆E2/∆E3 and control mice.
In the triple mutant, Wap levels at day 1 of lactation were equivalent to those found for wild-type mice at day 14 of pregnancy ( Fig. 4d) ,
providing evidence that the tripartite STAT5-driven enhancer cluster is responsible for the activation of Wap at mid pregnancy. Although our mutational analyses validated the exceptional role of the tripartite STAT5-driven super-enhancer, the consequences of individual and combined mutations on the binding of other transcription factors and the establishment of H3K27ac peaks remained unknown. We therefore investigated chromatin configuration and transcription factor binding at the Wap super-enhancer in mammary tissue derived from mice with the constituent enhancers mutated individually or in combination. The ∆E3 mutation not only led to loss of STAT5A binding but unexpectedly also led to the complete absence of GR binding and DNase I hypersensitivity and to lower H3K27ac levels at E3 (Fig. 5a, left) . The mammaryspecific Lao1 gene served as a control and was not affected by the mutations (Fig. 5a,  right) . In contrast, some STAT5A binding was retained upon deletion of the GAS site in E1 (∆E1a), and GR and MED1 binding were largely intact, as was the H3K27ac profile Figure 4 In vivo functions of individual enhancers in the mammaryspecific Wap super-enhancer. (a) Genomic features of E1, E2 and E3 in the Wap locus. H3K4me3, trimethylation of histone H3 at lysine 4. (b) Schematics of the genomes for single-enhancer mutants (∆E1a, ∆E2 and ∆E3) and mutants with STAT5 sites deleted in combination (∆E1a/ ∆E2, ∆E2/∆E3 and ∆E1a/∆E2/∆E3). The exact positions of the deletions are shown in supplementary Figure 9 . WT, wild type. (c) Wap mRNA levels in mammary tissues from mice carrying single enhancer mutations (∆E1a, ∆E2 and ∆E3) or mutations in combination (∆E1a/∆E2, ∆E2/∆E3 and ∆E1a/∆E2/∆E3) at day 1 of lactation. Wap mRNA levels were measured by qRT-PCR and normalized to Gapdh levels. Results are shown as the means ± s.e.m. of independent biological replicates (WT, n = 9; ∆E1a, n = 7; ∆E2, n = 10; ∆E3, n = 7; ∆E1a/∆E2, n = 3; ∆E2/∆E3, n = 3; ∆E1a/∆E2/∆E3, n = 3). A two-tailed unpaired t test was used to evaluate the statistical significance of differences between wild-type mice and each mutant group: *P < 0.05, **P < 0.001, ***P < 0.0001, ****P < 0.00001. Wap expression was reduced by approximately 91% in ∆E3 mutant mice and by over 99.9% in ∆E1a/∆E2/∆E3 mutant mice. (d) Comparison of Wap mRNA levels in mammary tissues from ∆E1a/∆E2/∆E3 mutant mice at day 1 of lactation and wild-type controls at different stages (day 1 of lactation and day 14 of pregnancy). Results are shown as log 10 -transformed means (error bars, s.e.m.; n = 3 mice per group). Wap expression was reduced by 1,000-fold in ∆E1a/∆E2/∆E3 mutant mice in comparison to wild-type mice at day 1 of lactation but was equivalent to that of wild-type mice at day 14 of pregnancy. The data for STAT5A, GR and H3K27ac ChIPseq are representative of biological duplicates. STAT5A binding was reduced at E1 and E2, and GR binding and H3K27ac marks were retained in mammary tissue from ∆E1a/∆E2 mutants. STAT5A and GR binding and H3K27ac marks were completely absent at E2 and E3 in mammary tissue from ∆E1a/∆E2/∆E3 mutants, although residual signal was retained at E1. (c) STAT5A ChIP-seq profiles in mice with enhancers mutated individually or in combination. STAT5A binding at E3 has the most prominent role in regulation of the Wap super-enhancer.
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A r t i c l e s ( Fig. 5a ), suggesting that this enhancer had retained limited integrity. Similarly, the chromatin landscape of E2, including H3K27ac, seemed largely intact upon deletion of the underlying STAT5-binding site (Fig. 5a) . The retention of the epigenetic profiles of E1 and E2 in the respective mutants is in agreement with the relatively modest contribution of these enhancers to Wap expression. In contrast, E3 is exceptional in that loss of STAT5 binding precluded the establishment of active enhancer features at this site, in agreement with the more than 90% reduction in Wap activity observed in the ∆E3 mutant. We propose that STAT5 is a key factor in the establishment of E3, whereas E1 and E2 are established, at least partially, in the absence of STAT5. The rather modest functional consequences of the ∆E1a and ∆E2 mutations are mirrored in the retention of GR binding and H3K27ac marks in mutants (Fig. 5b) . STAT5A ChIP-seq experiments indicated that loss of individual STAT5-binding sites had limited consequences for the remaining intact constituent enhancers (Fig. 5c) . However, combined loss of the dominant E3 enhancer and E2 seemed to affect occupancy of the proximal E1 element. Most notably, loss of all three STAT5-binding sites largely abolished the establishment of active chromatin over the whole super-enhancer, particularly at E2 and E3 (Fig. 5b) , in agreement with the complete loss of Wap activation during pregnancy in the corresponding mutant mice (Fig. 4c) .
The residual binding of GR in the E1 region was insufficient to convey any meaningful activation.
A seed enhancer in the Wap super-enhancer
The importance of STAT5 at E1 is limited and loss of the STAT5-binding site in this enhancer did not affect the overall enhancer profile, suggesting that establishment of the E1 enhancer might require the presence of additional transcription factors, possibly NFIB and ELF5, which bind close to STAT5 (refs. 14,15,53,54) ( Fig. 6a and Supplementary Fig. 10) . CRISPR/Cas9 genome editing was used to generate mice lacking the GAS site and the juxtaposed NFIB motif (∆E1b), and homologous recombination in embryonic stem cells was used to introduce point mutations into the GAS site and the NFIB and ELF5 motifs (∆E1c) (Fig. 6a) . Combined inactivation of the GAS site and the NFIB motif resulted in a reduction in Wap mRNA levels of approximately 70% (Fig. 6b) , suggesting that NFIB is not essential for the full activity of the E1 enhancer. Although studies using a Wap transgene containing 800 bp of the 5′ flanking sequence, and thus lacking E2 and E3 (refs. 48,55) , concluded that NFIB was essential for gene activity 14, 15 , this was not the case for the endogenous gene. ChIP-seq experiments confirmed loss of NFIB binding to mutant E1 and also demonstrated that ELF5 binding was unaffected ( Supplementary Fig. 11) .
The combined roles of STAT5, NFIB and ELF5 were investigated in mice carrying point mutations at all three sites (∆E1c) ( Fig. 6a  and Supplementary Fig. 11 ). Unexpectedly, mutations in these three sites incapacitated the entire Wap locus (Fig. 6b) . Moreover, E2 and E3 failed to be established during pregnancy, as demonstrated by the absence of transcription factor binding and H3K27ac marks (Fig. 6c) . The complete absence of DNase I hypersensitivity suggests that the super-enhancer had not undergone any priming and was unable to respond to pregnancy hormones. Collectively, these data indicate that the joint binding of three transcription factors at E1 provides an epicenter required for the activation of this mammary-specific locus and the recruitment of additional enhancers in response to hormonal stimuli during pregnancy. The super-enhancer that underlies the 1,000-fold induction in Wap expression during pregnancy is built on STAT5 binding to three individual enhancers with distinct properties. Notably, the Nfib and Elf5 genes also seem to be under the control of STAT5-driven enhancers (Supplementary Fig. 12 ).
DISCUSSION
Although super-enhancers have been identified in diverse cell types 49, [56] [57] [58] , there has been scant genetic proof of their biological relevance in vivo (Supplementary Table 2) . Similarly, the individual and combined contributions of constituent enhancers within superenhancers have not been investigated through genetic dissection in mice 24, 25, 56 . Our study now provides compelling genetic evidence that a unique mammary-specific hormone-regulated super-enhancer controls expression of the Wap gene during pregnancy and that the embedded constituent enhancers making up this super-enhancer Wap mRNA levels were measured by qRT-PCR and normalized to Gapdh levels. Results are shown as the means ± s.e.m. of independent biological replicates (WT, n = 9; ∆E1a, n = 7; ∆E1b, n = 7; ∆E1c, n = 5). A twotailed unpaired t test was used to evaluate the statistical significance of differences between wild-type mice and each mutant group: **P < 0.001, ***P < 0.0001, ****P < 0.00001. Wap expression levels in ∆E1a and ∆E1b were not significantly different (P = 0.5). Wap expression was reduced by 99.7% in ∆E1c mutant mice. (c) Genomic features of ∆E1b and ∆E1c mutant mice. The data for STAT5A and H3K27ac ChIP-seq are representative of biological duplicates. STAT5A binding and H3K27ac marks were reduced at E1 in mammary tissue from ∆E1b mutants. STAT5A and GR binding, H3K27ac marks and DHSs were absent at the three individual enhancers (E1, E2 and E3) in mammary tissue from ∆E1c mutants. An asterisk indicates enhancer sites that showed prominent reduction in STAT5A and H3K27ac intensity.
npg
A r t i c l e s provide distinct contributions to this regulation. In the case studied, the most distal enhancer seems to do the 'heavy lifting' , whereas the proximal ones individually have more modest activity. Thus, our mouse study supports the notion of a functional hierarchy within the STAT5-driven Wap super-enhancer. Notably, however, all three STAT5-binding sites were required to achieve the 1,000-fold induction in Wap expression during pregnancy. Mutational studies of the constituent enhancers in an erythroid super-enhancer in a cell line also demonstrated that the most distal enhancer was the most potent 34 . Additional genetic studies are needed to determine whether this is a general strategy used by other cell-type-specific superenhancers in vivo.
The establishment of a seed enhancer in the Wap super-enhancer during pregnancy depends on three mammary-enriched transcription factors, and the presence of this seed enhancer is required to launch the two accessory enhancers, leading to the full induction of gene expression. Although our data demonstrate that the formation of E2 and E3 depends on E1, suggesting that the Wap enhancer cluster could be viewed as a unique regulatory ensemble, we would argue that defining super-enhancers solely on the basis of ChIP-seq experiments and specific algorithms to identify peak patterns does not necessarily demonstrate that they are all special biological entities. Despite all super-enhancers having equivalent patterns of transcription factor binding, only half were associated with the induction of genes highly expressed during pregnancy by STAT5, the principal transcription factor used to define mammary-specific super-enhancers. Moreover, the range over which gene expression was induced by these superenhancers covered four orders of magnitude, and there seemed to be no obvious correlation between transcription factor occupancy and induction of gene expression. Although increased and progressive occupancy of super-enhancers was observed during pregnancy, this did not necessarily parallel induction of expression for the associated genes. Careful examination and functional testing of other superenhancers is necessary to draw any general conclusions regarding their biological relevance.
Although STAT family members are key in controlling cell lineages, likely through the cell-type-restricted activity of enhancers 10, 56, [59] [60] [61] [62] , studies with knockout mice have only provided limited insight into the contributions of individual STAT isoforms to specific super-enhancers and their embedded constituent enhancers. Loss of either Stat3 or Stat5a and Stat5b from the mouse genome results in the absence of specific T cell populations [63] [64] [65] [66] and mammary epithelium 6 , making it difficult to assess the contributions of these transcription factors to lineage-specific super-enhancers. Using genome editing to target individual enhancers avoids the systemic pitfalls encountered in mice lacking transcription factors, either in the germ line or specific cell types. Such an approach allows for a functional appraisal of predicted enhancer structures in the context of an otherwise uncompromised organism 67 . This is particularly relevant for T cells and mammary epithelium, whose lineages fail to develop in the absence of specific cytokine-or hormone-sensing transcription factors. In summary, our study provides evidence that a genome-wide survey of putative superenhancers, coupled with targeted genomic editing, can provide mechanistic insight into complex organ-specific and cytokine-regulated gene regulatory modules.
URLs. MIT CRISPR Design tool, http://crispr.mit.edu/; R Project for Statistical Computing, https://www.R-project.org/; dplyr, https://CRAN.R-project.org/package=dplyr; Power Analysis, https:// CRAN.R-project.org/package=pwr.
METHODS
Methods and any associated references are available in the online version of the paper. Accession codes. All ChIP-seq and DNase-seq data sets have been deposited in the Gene Expression Omnibus (GEO) under accession GSE74826. Liver and T cell data are available under accessions GSE31578, GSE27158 and GSE31039. RNA-seq data from mammary tissue are available under accessions GSE70440 and GSE37646. The T cell and liver RNA-seq data are available under accessions GSE48138 and GSE66140.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
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